1.
Global Cancer Observatory.
http://gco.iarc.fr/.
Accessed July 2,
2017.
2.
Travis WD,
Brambilla E,
Noguchi M,
et al.
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma.
J Thorac Oncol Off Publ Int Assoc Study Lung Cancer.
2011;6(2):244–285.
3.
Godoy MCB,
Naidich DP.
Subsolid Pulmonary Nodules and the Spectrum of Peripheral Adenocarcinomas of the Lung: Recommended Interim Guidelines for Assessment and Management.
Radiology.
2009;253(3):606–622.
4.
Austin JH,
Garg K,
Aberle D,
et al.
Radiologic implications of the 2011 classification of adenocarcinoma of the lung.
Radiology.
2013;266(1):62–71.
5.
Naidich DP,
Bankier AA,
MacMahon H,
et al.
Recommendations for the management of subsolid pulmonary nodules detected at CT: a statement from the Fleischner Society.
Radiology.
2013;266(1):304–317.
6.
MacMahon H,
Naidich DP,
Goo JM,
et al.
Guidelines for Management of Incidental Pulmonary Nodules Detected on CT Images: From the Fleischner Society 2017.
Radiology.
2017;284(1):228–243.
7.
Travis WD,
Brambilla E,
Riely GJ.
New Pathologic Classification of Lung Cancer: Relevance for Clinical Practice and Clinical Trials.
J Clin Oncol.
2013;31(8):992–1001.
8.
Chan BA,
Hughes BG.
Targeted therapy for non-small cell lung cancer: current standards and the promise of the future.
Transl Lung Cancer Res.
2015;4(1):36.
9.
Smith RP,
Netter FH,
Machado CAG,
Netter FH,
editors.
The Netter collection of medical illustrations.
2nd ed.
Philadelphia,
PA: Elsevier; 2011.
10.
Russell PA,
Wainer Z,
Wright GM,
Daniels M,
Conron M,
Williams RA.
Does lung adenocarcinoma subtype predict patient survival?: A clinicopathologic study based on the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary lung adenocarcinoma classification.
J Thorac Oncol Off Publ Int Assoc Study Lung Cancer.
2011;6(9):1496–1504.
11.
Eguchi T,
Kadota K,
Park BJ,
Travis WD,
Jones DR,
Adusumilli PS.
The New IASLC-ATS-ERS Lung Adenocarcinoma Classification: What the Surgeon Should Know.
Semin Thorac Cardiovasc Surg.
2014;26(3):210–222.
12.
Raghunath S,
Maldonado F,
Rajagopalan S,
et al.
Noninvasive Risk Stratification of Lung Adenocarcinoma using Quantitative Computed Tomography.
J Thorac Oncol.
2014;9(11):1698–1703.
13.
Li M,
Narayan V,
Gill RR,
et al.
Computer-Aided Diagnosis of Ground-Glass Opacity Nodules Using Open-Source Software for Quantifying Tumor Heterogeneity.
Am J Roentgenol.
2017;209(6):1216–1227.
14.
Nishino M,
Hatabu H,
Johnson BE,
McLoud TC.
State of the Art: Response Assessment in Lung Cancer in the Era of Genomic Medicine.
Radiology.
2014;271(1):6–27.
15.
Wang GX,
Guo LQ,
Gainor JF,
Fintelmann FJ.
Immune Checkpoint Inhibitors in Lung Cancer: Imaging Considerations.
Am J Roentgenol.
2017;209(3):567–575.
16.
Tirkes T,
Hollar MA,
Tann M,
Kohli MD,
Akisik F,
Sandrasegaran K.
Response Criteria in Oncologic Imaging: Review of Traditional and New Criteria.
RadioGraphics.
2013;33(5):1323–1341.
17.
Benegas Urteaga M,
Volmer I.
New radiological approaches in lung cancer to evaluate tumor response to new treatments (targeted therapies and immunotherapy): morphological and functionalimaging.
Boston; 2017.